All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On May 21, positive topline results of the pivotal trial evaluating belumosudil in patients with chronic graft-versus-disease (cGvHD) were announced.1 Belumosudil (KD025) is a selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), involved in modulating inflammatory response. The ongoing open-label, phase II ROCKstar study (KD025-213, NCT03640481) is being conducted in adults and adolescents with cGvHD who received ≥ 2 prior lines of systemic therapy.
Previously at the interim analysis, the study had met the primary endpoint of overall response rates (ORR). Now, the topline results confirmed the finding reporting ORR of 73% (95% CI, 60–83%; p < 0. 0001) and 74% (95% CI, 62 –84%; p < 0.001) with 200 mg once and twice-daily doses of belumosudil, respectively. The complete responses were observed across all affected organ systems. At the time of the primary analysis, after a median treatment duration of 29 weeks, the median duration of response has not been reached. Almost half of the patients (49%) maintained their response for ≥ 20 weeks. However, the data is still maturing. The toxicity of belumosudil has been manageable, with no reports of cytomegalovirus infections/reactivations or serious treatment-related cytopenias.
New Drug Application submission to the U.S. Food and Drug Administration (FDA) for belumosudil (KD025) is planned for the last quarter of this year. Previously, the drug has been granted FDA Breakthrough Therapy Designation for the treatment of patients with cGVHD and an Orphan Drug Designation.
Belumosudil is also being investigated in a phase II clinical trial in adults with diffuse cutaneous systemic sclerosis (KD025-209).
Kadmon. Kadmon announces positive topline results of pivotal trial of belumosudil (KD025) in chronic graft-versus-host disease.https://investors.kadmon.com/node/8806. Published May 21, 2020. Accessed May 22, 2020.
Subscribe to get the best content related to GvHD delivered to your inbox